Pictet Asset Management SA Sells 1,792,764 Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)

Pictet Asset Management SA trimmed its position in Neoleukin Therapeutics, Inc. (NASDAQ:NLTXGet Rating) by 69.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 781,551 shares of the company’s stock after selling 1,792,764 shares during the quarter. Pictet Asset Management SA owned 1.84% of Neoleukin Therapeutics worth $805,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new stake in Neoleukin Therapeutics during the 1st quarter valued at $27,000. Kestra Private Wealth Services LLC boosted its holdings in shares of Neoleukin Therapeutics by 100.0% during the first quarter. Kestra Private Wealth Services LLC now owns 24,000 shares of the company’s stock worth $45,000 after purchasing an additional 12,000 shares during the period. Simon Quick Advisors LLC purchased a new stake in shares of Neoleukin Therapeutics during the second quarter worth about $49,000. Shay Capital LLC bought a new stake in shares of Neoleukin Therapeutics in the first quarter worth about $52,000. Finally, Adviser Investments LLC increased its holdings in Neoleukin Therapeutics by 39.7% during the 2nd quarter. Adviser Investments LLC now owns 65,404 shares of the company’s stock valued at $67,000 after purchasing an additional 18,587 shares during the period. 49.19% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NLTX shares. Stifel Nicolaus cut Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 15th. HC Wainwright cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 16th. Canaccord Genuity Group cut Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 15th. Mizuho cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $21.00 to $2.00 in a research note on Tuesday, November 15th. Finally, Guggenheim cut Neoleukin Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Neoleukin Therapeutics has a consensus rating of “Hold” and an average target price of $6.00.

Neoleukin Therapeutics Stock Down 4.7 %

Shares of NLTX stock opened at $0.43 on Wednesday. The stock has a market cap of $18.31 million, a price-to-earnings ratio of -0.40 and a beta of 1.18. The business’s fifty day moving average is $0.62 and its 200 day moving average is $0.90. Neoleukin Therapeutics, Inc. has a twelve month low of $0.38 and a twelve month high of $5.76.

About Neoleukin Therapeutics

(Get Rating)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Featured Articles

Want to see what other hedge funds are holding NLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neoleukin Therapeutics, Inc. (NASDAQ:NLTXGet Rating).

Institutional Ownership by Quarter for Neoleukin Therapeutics (NASDAQ:NLTX)

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.